The Journal of dermatological treatment · 2018
Methotrexate treatment of generalized granuloma annulare: a retrospective case series.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Naka Fludiona, Strober Bruce E
Аннотация
BACKGROUND: Management of generalized granuloma annulare (GGA) poses challenges for both patients and dermatologists. Currently, there are no established first-line therapies for GGA and the available therapeutic modalities are based on individual case reports and a few small case series. Further, there are limited publications assessing the efficacy of methotrexate in treating GGA.
OBJECTIVE: To evaluate the efficacy and adverse effects associated with methotrexate treatment of GGA.
METHODS: Descriptive retrospective case series of 11 patients with GGA receiving methotrexate.
RESULTS: Sixty four percent of patients receiving methotrexate noted improvement of their skin disease, of which 43% achieved complete clearance and 57% partial clearance. Initial dose of methotrexate ranged from 12.5 to 15 mg weekly, administered either orally or subcutaneously. The majority of patients tolerated the treatment well. However, 18% of patients experienced the adverse effects of either GI upset or hair loss.
LIMITATIONS: This case series lacks a control group and therefore has low internal validity. The lack of a disease severity and therapy responsiveness measurement tool made quantifying disease improvement inexact.
CONCLUSIONS: Methotrexate can be a successful and well-tolerated treatment option for patients with generalized GA.
OBJECTIVE: To evaluate the efficacy and adverse effects associated with methotrexate treatment of GGA.
METHODS: Descriptive retrospective case series of 11 patients with GGA receiving methotrexate.
RESULTS: Sixty four percent of patients receiving methotrexate noted improvement of their skin disease, of which 43% achieved complete clearance and 57% partial clearance. Initial dose of methotrexate ranged from 12.5 to 15 mg weekly, administered either orally or subcutaneously. The majority of patients tolerated the treatment well. However, 18% of patients experienced the adverse effects of either GI upset or hair loss.
LIMITATIONS: This case series lacks a control group and therefore has low internal validity. The lack of a disease severity and therapy responsiveness measurement tool made quantifying disease improvement inexact.
CONCLUSIONS: Methotrexate can be a successful and well-tolerated treatment option for patients with generalized GA.